Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Other Non-Current Liabilities (2016 - 2025)

Surgery Partners' Other Non-Current Liabilities history spans 12 years, with the latest figure at $41.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 36.42% year-over-year to $41.2 million; the TTM value through Dec 2025 reached $41.2 million, up 36.42%, while the annual FY2025 figure was $41.2 million, 36.42% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $41.2 million at Surgery Partners, up from $38.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $151.7 million in Q2 2021 and bottomed at $21.1 million in Q2 2024.
  • The 5-year median for Other Non-Current Liabilities is $77.1 million (2022), against an average of $70.6 million.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 74.33% in 2024 before it surged 72.04% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $87.0 million in 2021, then dropped by 13.33% to $75.4 million in 2022, then crashed by 45.49% to $41.1 million in 2023, then dropped by 26.52% to $30.2 million in 2024, then surged by 36.42% to $41.2 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Other Non-Current Liabilities are $41.2 million (Q4 2025), $38.1 million (Q3 2025), and $36.3 million (Q2 2025).